On the afternoon of October 11, Shenzhen Cell Valley Biopharmaceutical Co., Ltd. successfully won the bid with an absolute advantage in the competitive bidding for the "GMP-Grade CAR-T Cell Preparation" project of Huazhong University of Science and Technology Union Shenzhen Hospital, relying on its superior product quality, solid and efficient service style, top-tier technical team, and excellent corporate reputation.

Throughout the bidding process, the company went through numerous rounds of communication, negotiation, and uation—from the initial determination of bidding intention, to the submission of bidding documents and quotations, and to the intense negotiations at the bidding site—all of which witnessed the down-to-earth and meticulous service style of the Shenzhen Cell Valley team.

This successful bid marks the official launch of the tripartite collaboration on the "Clinical Study of CD19-CD22 Dual-Target CAR-T Based on Retroviral Vectors" between Shenzhen Cell Valley Biopharmaceutical Co., Ltd., Peking University Shenzhen Graduate School, and Huazhong University of Science and Technology Union Shenzhen Hospital. Shenzhen Cell Valley is committed to empowering R&D, accelerating translation, reducing industrialization costs, and bringing new hope to patients—ensuring that quality products leave the laboratory and truly serve clinical needs and are applied in clinical practice.

This bid win is another milestone in the close cooperation between Shenzhen Cell Valley and the Hematology Department of Huazhong University of Science and Technology Union Shenzhen Hospital. Going forward, the two parties will further strengthen their collaboration in clinical research on CAR-T and other cellular immunotherapy products. Shenzhen Cell Valley provides safe, high-quality, and affordable GMP-grade retroviral vectors and cell products, ensuring the safety and efficacy of cell products. At the same time, it emphasizes the close integration of research and clinical practice, striving to improve treatment outcomes and promote the overall development of the cell and gene therapy industry.

About the Hematology Department of Huazhong University of Science and Technology Union Shenzhen Hospital

The Hematology Department of Huazhong University of Science and Technology Union Shenzhen Hospital is a clinical research-oriented department integrating medical care, teaching, and research. Professor Guo Zhi from the Hematology Department of the Seventh Medical Center of the Chinese People's Liberation Army General Hospital serves as the discipline leader. The Hematology Department team is dedicated to the standardized treatment of hematological tumors such as lymphoma, leukemia, and myeloma, as well as hematopoietic stem cell transplantation, providing high-level diagnosis and treatment of hematological system diseases including hematological tumors. The department currently has 78 beds across three wards, 2 advanced Class 100 laminar flow transplantation rooms, 10 Class 100 laminar flow beds, 14 physicians (including 7 with senior professional titles), and 3 research and technical personnel. All physicians hold master's degrees or above, including 7 Ph.D. holders (4 currently pursuing doctoral degrees). The Hematology Department is a hematological specialty focusing on the standardized treatment of hematological tumors such as lymphoma, leukemia, and myeloma, as well as hematopoietic stem cell transplantation. It is the hematology specialty with the greatest influence, largest scale, highest academic standing, most hematological tumor admissions, and most advanced laboratory in the Shenzhen region.